with first data readout expected in summer 2025 European Committee for Medicinal Products for Human Use (CHMP) review of ...
Applied Therapeutics, Inc. (Nasdaq: APLT) (the“Company”), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications ...
BeiGene's TEVIMBRA expands for cancer treatment, and BRUKINSA sales soar 107%. See why BGNE stock presents upside potential ...
PTC Therapeutics' NDA resubmission of Translarna was based on data from Study 041 and the long-term STRIDE registry. No PDUFA action date was provided for regulators.
Four months after Europe's Committee for Medicinal Products for Human Use (CHMP) rejected Apellis’ GA application for Syfovre for a second time, Astellas has withdrawn its application for the approval ...
The Committee for Medicinal Products for Human Use (CHMP) has specifically recommended that the drug be used to treat patients with stage one or two polyneuropathy (PN), a condition that affects ...
Hosted on MSN19d
AstraZeneca Receives CHMP's Approval for Wainzua in EuropeAstraZeneca AZN and Ionis Pharmaceuticals IONS announced that the Committee for Medicinal Products for Human Use (CHMP) has ...
Novo Nordisk’s Alhemo (concizumab) has been recommended by the European Medicines Agency’s human medicines committee to prevent bleeding in haemophilia patients aged 12 years or older. If approved, ...
Credit: Olena Yakobchuk/Shutterstock. The European Union’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of AstraZeneca and Ionis Pharmaceuticals’ Wainzua ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback